Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Saudi Arabia Pharmaceuticals Market: By Product Type, By Diseases Type, By Distribution Channel .
Saudi Arabia Pharmaceuticals Market: By Product Type, By Diseases Type, By Distribution Channel .
Saudi Arabia Pharmaceuticals Market size was valued at US$ 7,979.17 million in 2022 and is poised to grow at a CAGR of 6.8% from 2024-2030. The desire for branded or second-generation pharmaceuticals among key stakeholders such as patients and prescribers is creating a plethora of opportunities for global companies in the country. These brands are typically distributed through partnerships with local pharmaceutical businesses, which enable new entrants into the market to access a larger number of pharmacies around the country. Furthermore, Saudi Arabia is heavily reliant on pharmaceutical imports from diverse geographies, which are mostly dominated by global pharmaceutical behemoths that supply innovative and second-tier brands through local companies. Brand loyalty for multinational firm products can be related to the medication's quality and accessibility, which helps multinational players get a bigger market share.
The preference for branded drugs or second brands among key stakeholders such as patients and prescribers are creating the ample opportunities for multinational players in the country. These brands generally sold through the alliance with local pharmaceutical companies which help the new players in the market to reach wider pharmacies across the country. Moreover, Saudi Arabia largely dependent upon imports for pharmaceuticals from various geographies and mainly dominated by the multinational pharmaceutical giants who offer innovative and second brands through local players. Brand loyalty for multinational company products can be attributed to the quality and accessibility of the medication which helps in garnering larger market share by multinational players. Rising prevalence of various chronic diseases such as diabetes, ischemic heart disease, stroke, obesity, hypertension, cancer among Saudi nationals is creating market demand pharmaceuticals in the country. Drug treating chronic ailments are expected to provide lucrative market opportunities for the players in the country. Moreover, these chronic diseases are a major cause of death in Saudi Arabia.
|
Report Benchmarks |
Details |
|
Market Size in 2022 |
US$ 7,979.17 million |
|
By Product Type |
|
|
By Disease Type |
|
|
By Distribution Channel |
|
Download Free Sample Report
The Saudi Arabia pharmaceuticals market size was valued at US$ 7,979.17 million in 2022
GlaxoSmithKline plc. , Riyadh Pharma , SPIMACO, Tabuk Pharmaceuticals Manufacturing Co.
The Saudi Arabia pharmaceuticals market segments are by product type, disease type and distribution channel
1. Research Methodology
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. Scope of Study
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. Executive summary
4. Saudi Arabia Pharmaceuticals Market Dynamics
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. Unique Features of the Report
5.1. Competition analysis
5.2. Regulatory landscape
5.3. PESTLE analysis
5.4. Porter’s analysis
6. Saudi Arabia Pharmaceuticals Market Analysis, By Product Type, 2018 - 2022 and Forecast, 2023 - 2029
6.1. Prescription Products
6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. OTC Products
6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. Saudi Arabia Pharmaceuticals Market Forecast, By Disease Type Analysis, 2018 - 2022 and Forecast, 2023 - 2029
7.1. Diabetes
7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Cardiovascular Diseases
7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Cancer
7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Neurological Disorders
7.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Obesity
7.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.6. Infectious Diseases
7.6.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.7. Others
7.7.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. Saudi Arabia Pharmaceuticals Market Forecast, By Distribution Channel Analysis, 2018 - 2022 and Forecast, 2023 - 2029
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. Competition Landscape
9.1. Strategic Dashboard of Top Market Players
9.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
9.2.1. GlaxoSmithKline plc. (UK)
9.2.2. Jamjoom Pharma (Saudi Arabia)
9.2.3. Juphar (UAE)
9.2.4. Novartis AG (Switzerland)
9.2.5. Pfizer Inc. (US)
9.2.6. Riyadh Pharma (Saudi Arabia)
9.2.7. Sanofi (France)
9.2.8. SPIMACO (Saudi Arabia)
9.2.9. Tabuk Pharmaceuticals Manufacturing Co. (Saudi Arabia)
10. Key Assumptions and Acronyms
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.